Mandana Khalili, MD

Mandana Khalili
Global Health Sciences Faculty Affiliate

Phone: 415-206-4766
UCSF Box: 0862
Email: [email protected]
UCSF Profile

Project Sponsor Location(s) Topics Start End
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults with Compensated Chronic Hepatitis B Idenix Pharmaceuticals, Inc. United States Infectious Disease
Insulin Resistance in HCV Infection NIH National Institute of Diabetes and Digestive and Kidney Diseases United States Sexually Transmitted Infections (STIs)
PEGASYS plus Copegus in treatment-naïve Latino patients with chronic hepatitis C-genotype 1, as compared to treatment-naïve non-Latino White patients with chronic hepatitis C-genotype 1 Hoffman-LaRoche, Ltd. United States Infectious Disease
Hepatocellular Carcinoma Screening Practices in Hepatitis B (HBV) Infected Asian Americans University of California Davis United States Infectious Disease
Hcv-Induced Alterations in Glucose Metabolism NIH National Institute of Diabetes and Digestive and Kidney Diseases United States Infectious Disease, Diabetes
Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus Pharmasset, Inc. United States Infectious Disease, Pharmacology and Drug Treatment
Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus Pharmasset, Inc. United States Infectious Disease
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study University of Florida United States
BMS-790052 with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Peginterferon Alfa plus Bristol-Myers Squibb Company Mexico; Argentina; Puerto Rico; Australia
BMS-790052 with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 Bristol-Myers Squibb Company Egypt; Sweden; Mexico; Puerto Rico; Canada; Australia
Host and Viral Predictors of Prediabetes in at-risk Latinos with Chronic Hepatitis C (HCV) Bristol-Myers Squibb Company United States Infectious Disease, Diabetes
Screening and Management of Chronic Hepatitis B Virus Infection: A Survey of San Francisco Health Care Providers Bristol-Myers Squibb Company United States Infectious Disease
Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos United States
GS-US-248-0122: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection Gilead Sciences, Inc. United States Infectious Disease
AI452-020-0092: Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-naïve or Re Bristol-Myers Squibb Company United States Infectious Disease, Pharmacology and Drug Treatment
Patients' HBV Knowledge, Attitudes, Barriers to HBV Care and HBV Treatment Gilead Sciences, Inc. United States
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are on Dialysis for End Stage Renal Disease Gilead Sciences, Inc. United States Infectious Disease
Mentoring Multidisciplinary Patient-Oriented Research in Viral Hepatitis NIH National Institute of Alcohol Abuse and Alcoholism United States Sexually Transmitted Infections (STIs)
Pegylated Interferon Lambda w/wo Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 Bristol-Myers Squibb Company South Korea; Japan; India; Singapore; Belgium; Finland; France; Greece; Italy; Netherlands; Russia; United Kingdom; Mexico; Argentina; Brazil; Chile; Canada; Australia; New Zealand Sexually Transmitted Infections (STIs)
GS-US-367-1172: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Gilead Sciences, Inc. United States Infectious Disease, Pharmacology and Drug Treatment
Mentoring Multidisciplinary Patient-Oriented Research in Viral Hepatitis NIH National Institute of Alcohol Abuse and Alcoholism United States Infectious Disease, Residencies, Fellowships, and Postdoctoral Training
Alcohol's impact on immunological and virological profiles in HIV patients Indiana Univ-Purdue Univ Indianapolis United States HIV/AIDS, Immunology, Substance Abuse
HBV/HIV Co-Infection Research Network United States Sexually Transmitted Infections (STIs), HIV/AIDS